Anticancer drugs may also be of use in treating sickle-cell anemia, according to a recent study. The work represents the latest research on repositioning new pharmaceutical products in the marketplace. Sickle cell disease (SCD) is an inherited blood disorder caused by a genetic mutation that leads to the generation of a mutant form of the beta-globin chain of hemoglobin (Hb). Now, Calgene's Laure Moutouh-de Parseval and colleagues have shown that two anticancer drugs, lenalidomide and pomalidomide, which modulate the immune system are more effective than the standard SCD treatment, hydroxyurea. The same drugs may also benefit people with the blood disorder beta-thalassemia.